Endonovo Therapeutics (ENDVD) & Its Competitors Head to Head Contrast

Risk and Volatility

Endonovo Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics’ competitors have a beta of 11.34, meaning that their average share price is 1,034% more volatile than the S&P 500.

Earnings & Valuation

This table compares Endonovo Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Endonovo Therapeutics	$170,000.00	-$400,000.00	N/A
Endonovo Therapeutics Competitors	$434.13 million	-$68.27 million	-10.49

Endonovo Therapeutics’ competitors have higher revenue, but lower earnings than Endonovo Therapeutics. Endonovo Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Endonovo Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	-6,075.54%	N/A	-279.35%
Endonovo Therapeutics Competitors	-2,626.20%	-359.54%	-43.35%

Institutional & Insider Ownership

39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Endonovo Therapeutics competitors beat Endonovo Therapeutics on 6 of the 9 factors compared.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.